ARCHIVES

Talking Back: FDA Faces Challenges Over Avastin & Prostate Cancer Prevention

This article is from The Cancer Letter archive.

Vol. 37 No. 03 | January 21, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

Gene Delivery System Targets Tumor Blood Vessels In Dogs

March 27, 2009

DCT Board Approves Proposals For Increased Efforts With Biological Response Modifiers, Oks Contracts

November 9, 1979

Ethics Commission Acknowledges Weak Case For Mandatory Patient Compensation

April 23, 1982

Advisors Suggest Consortia For Lung Cancer Research.

November 9, 2001

Copeland Named Director, UF Cancer Center

February 10, 1995